Drugs / Lafutidine
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02759224 | Apr → Jul 2016 | gastric ulcer | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02581696 | Aug → Nov 2015 | peptic ulcer disease | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1 | NCT02658864 | Apr → Jun 2005 | chronic gastritis | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT01499368 | Nov 2011 → Nov 2012 | esophagitis | Boryung Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 3 | NCT00229424 | Apr 2005 → Oct 2006 | gastroesophageal reflux disease | Taiho Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02703896 | Jan 2012 | lung disorder | King Saud University | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Lafutidine | “Group S (lafutidine 10 mg)” NCT02703896 ↗ |
| Known as | Lafutidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1742461 ↗ |
| Action | Inhibit | “Histamine H2 receptor antagonist” CHEMBL1742461 ↗ |
| Modality | Small molecule | — CHEMBL1742461 ↗ |
| Route | Oral | “Oral administration of lafutidine by 20mg/day along with famotidine placebo” NCT00229424 ↗ |
| Target | HRH2 | “Histamine H2 receptor antagonist” CHEMBL1742461 ↗ |